Business Context and Reporting Period
Company: ORAGENICS INC
Filing Type: Form 8-K (Current Report)
Date of Report: December 11, 2006
Event: Termination of a Material Definitive Agreement regarding warrant redemption.
Key Financial Metrics
This filing does not provide standard financial statements (revenue, profit, cash flow, or debt). The only financial data disclosed relates to the warrant exercise terms:
- Warrant Exercise Price: $0.60 per share.
- Shares Subject to Warrants: Approximately 1.4 million shares.
- Trigger Price: Stock price exceeded $1.20 per share for 15 consecutive days.
Material Changes
The Company exercised its right to accelerate the expiration date of warrants issued in connection with its December 2005 private financing. The new expiration date is set for January 8, 2007. This action was triggered by the Company's stock price remaining above $1.20 per share for 15 consecutive days.
Outlook and Management Commentary
Management notified warrant holders of the accelerated expiration. Holders retain the right to exercise the warrants to acquire common stock at $0.60 per share but must do so by the new deadline of January 8, 2007. The filing references a press release (Exhibit 99.1) for further details on recent events.
Investor Verification Checklist
- Verify the current trading price of ORAGENICS stock relative to the $1.20 trigger and $0.60 exercise price.
- Confirm the exact number of outstanding warrants subject to the accelerated expiration (stated as approximately 1.4 million).
- Review the attached press release (Exhibit 99.1) for any additional context on the December 2005 financing.
- Monitor whether warrant holders exercise their rights before the January 8, 2007 deadline, which could impact share count and dilution.